Highlights From Community Oncology Global Congress 2026, Day 1
VIRO 2026 – Global Voices in Renal Oncology
Phase 2 NEST Trial: Neoadjuvant BOT/BAL in Localized Colon Cancer
SKYSCRAPER-07: Atezolizumab ± Tiragolumab After dCRT in Unresectable ESCC
Michelle Mitchell: HPV Self-Testing Marks a Major Step Toward Eliminating Cervical Cancer
When EGFR-Mutant NSCLC Becomes SCLC: Can Immunotherapy Become Relevant Again?
Bristol Myers Squibb Invests $173 Million to Expand U.S. Radiopharmaceutical Manufacturing
Manish Shah: Phase 2 NEST Trial Shows Promising Neoadjuvant BOT/BAL Results in Colon Cancer
Identifies low-risk febrile neutropenia patients using the MASCC (Multinational Association for Supportive Care in Cancer) risk index.
Check if YES (0 points), leave unchecked if NO (+5 points)
Check if YES (0 points), leave unchecked if NO (+4 points)
Check if YES (0 points), leave unchecked if NO (+3 points)
Check if YES (+3 points), leave unchecked if NO (0 points)
Check if YES (+2 points), leave unchecked if NO (0 points)
MASCC Risk Index Scoring:
Risk Classification:
